Nanobiotix S.A. (NBTX)
NASDAQ: NBTX · Real-Time Price · USD
4.600
0.00 (0.00%)
Jun 17, 2025, 4:00 PM - Market closed
Nanobiotix Revenue
In the year 2024, Nanobiotix had annual revenue of -7.19M EUR, down -119.86%. Nanobiotix had revenue of -16.48M in the half year ending December 31, 2024, a decrease of -578.07%.
Revenue (ttm)
-7.19M EUR
Revenue Growth
-119.86%
P/S Ratio
-29.80
Revenue / Employee
-66,574 EUR
Employees
108
Market Cap
221.81M USD
Revenue Chart
* This company reports financials in EUR.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | -7.19M | -43.40M | -119.86% |
Dec 31, 2023 | 36.21M | 31.43M | 658.12% |
Dec 31, 2022 | 4.78M | 2.13M | 80.43% |
Dec 31, 2021 | 2.65M | 322.00K | 13.85% |
Dec 31, 2020 | 2.33M | -216.00K | -8.50% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
NBTX News
- 21 days ago - NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference - GlobeNewsWire
- 27 days ago - Nanobiotix Provides First Quarter 2025 Operational and Financial Update - GlobeNewsWire
- 5 weeks ago - Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ - GlobeNewsWire
- 6 weeks ago - Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer - GlobeNewsWire
- 7 weeks ago - Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call - GlobeNewsWire
- 2 months ago - Nanobiotix S.A. (NBTX) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results - GlobeNewsWire
- 2 months ago - NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025 - GlobeNewsWire